HuGE Literature Finder
Records
1
-
2
Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. Medical oncology (Northwood, London, England) 2018 Mar 35 (4): 51. Igarashi Ryoma, Inoue Takamitsu, Fujiyama Nobuhiro, Tsuchiya Norihiko, Numakura Kazuyuki, Kagaya Hideaki, Saito Mitsuru, Narita Shintaro, Satoh Shigeru, Niioka Takenori, Miura Masatomo, Habuchi Tomono |
Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma. Oncotarget 2018 Mar 9 (24): 17160-17170. Yamamoto Yoshiaki, Tsunedomi Ryouichi, Fujita Yusuke, Otori Toru, Ohba Mitsuyoshi, Kawai Yoshihisa, Hirata Hiroshi, Matsumoto Hiroaki, Haginaka Jun, Suzuki Shigeo, Dahiya Rajvir, Hamamoto Yoshihiko, Matsuyama Kenji, Hazama Shoichi, Nagano Hiroaki, Matsuyama Hideya |
- Page last reviewed:Jul 25, 2022
- Page last updated:Aug 10, 2022
- Content source: